Skip to main content
Retour
Watch Compare

CERO THERAPEUTICS HOLDINGS, INC.

Qualité des données : 83%
Également cotée sous CEROW OTC
CERO
OTC Manufacturing Chemicals
0,04 €
▲ 0,00 € (9,09%)
Cap. Boursière: 770 247,0
Prix
0,04 €
Cap. Boursière
770 247,0
Fourchette du Jour
0,03 € — 0,04 €
Fourchette 52 Semaines
0,03 € — 28,40 €
Volume
346 569
Ouverture 0,03 €
Moyenne 50J / 200J
0,04 €
8,86% below
Moyenne 50J / 200J
3,14 €
98,85% below

Quick Summary

Points Clés

Negative free cash flow of -186 609,0

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,30
Interest Coverage-330,32

Valorisation

PE (TTM)
-0,05
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,1 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -14,71 M
ROE N/A ROA -290,85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -186 609,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,30
Interest Coverage -330,32 Asset Turnover N/A
Working Capital -5,90 M Tangible Book Value -4,54 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,05 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24,23%
Market Cap 770 247,0 Enterprise Value -1,13 M
Per Share
EPS (Diluted TTM) -90,81 Revenue / Share N/A
FCF / Share -0,01 OCF / Share -0,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 1,27%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022
Revenue — — — —
Net Income -7,73 M -2,54 M -315 547,0 -667 736,0
EPS (Diluted) -18,15 — — —
Gross Profit — — — —
Operating Income -15,30 M -2,93 M — —
EBITDA — — — —
R&D Expenses 6,32 M — — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense -21 846,0 — — —
Income Tax — 94 819,0 -16 868,0 599 159,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022
Total Assets 6,21 M 8,56 M 180,08 M 42,37 M
Total Liabilities 8,10 M 14,32 M 9,25 M 39,90 M
Shareholders' Equity -1,89 M -14,20 M -7,67 M -10,76 M
Total Debt — — — —
Cash & Equivalents — 96 873,0 1,10 M 475 870,0
Current Assets 3,71 M — 1,36 M 42,37 M
Current Liabilities 7,40 M 5,17 M 98 072,0 30,75 M